Selective PDE4 inhibitors have recently been developed with the aim of improving the therapeutic index, as the PDE4 isoform is highly expressed on inflammatory cells involved in asthma and COPD, such as mast cells, eosinophils, T lymphocytes, macrophages and neutrophils[4, 5]. Here, PDE4A is linked to chronic obstructive pulmonary disease.